New cancer drug FL115 tested in humans for first time
NCT ID NCT06130722
First seen Jan 08, 2026 · Last updated May 10, 2026 · Updated 18 times
Summary
This early-phase study tested a new drug, FL115, in 18 adults with advanced solid tumors that no longer responded to standard treatments. The main goal was to check safety and find the right dose. Participants received the drug weekly, and doctors watched for side effects, especially a reaction called cytokine release syndrome. The study is complete, but it is too early to know if FL115 works as a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabriel Cancer Center
Canton, Ohio, 44718, United States
-
HOAG Memorial Hospital Presbyterian
Newport Beach, California, 92663, United States
-
Moores Cancer Center at UCSD Health
San Diego, California, 92037, United States
Conditions
Explore the condition pages connected to this study.